ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR Other Working Capital
Cash effect of changes in other operating assets and liabilities.
ProQR Therapeutics N.V.NASDAQ: PRQR
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital turns positive
Q1 FY2026 other working capital was €110.79K, compared with -€6.72M a year earlier. Trailing-twelve-month other working capital was -€10.48M. Over 3 fiscal years it compounded at +49.7% a year.
Context
- Other working capital amounted to 109.5% of revenue in FY2025, up 39.3 pp from a year earlier.
- Other working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other working capital holds near €110.79K or moves back toward the trailing-twelve-month quarterly average of -€2.62M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
EUR · from the cash flow
- Latest · FY2025
- (16.73M) EUR
- Year-over-year change
- -26.1%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (16.73M) | -26.1% |
| FY2024 | 2024-12-31 | (13.26M) | -127.1% |
| FY2023 | 2023-12-31 | 48.96M | +1080.9% |
| FY2022 | 2022-12-31 | (4.99M) | -120.0% |
| FY2021 | 2021-12-31 | 25.01M | — |
Other Working Capital vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.6% is the 6th highest of 11, against a peer median of +50.9%.
- Other working capital amounts to 78.0% of revenue for PRQR, versus a peer median of 116.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.48M USD | -373.0% | — | 122.7% | |
| LTM Mar 2026 | $19.64M USD | -71.6% | +51.1% | 43.3% | |
| LTM Mar 2026 | $16.02M USD | +649.3% | +102.5% | — | |
| LTM Mar 2026 | $12.07M USD | +107.2% | -30.5% | 210.3% | |
| LTM Mar 2026 | €10.48M EUR | -2.6% | +49.7% | 78.0% | |
| FY2025 | A$6.02M AUD | -311.0% | +56.9% | 119.5% | |
| LTM Mar 2026 | $4.33M USD | +147.2% | — | 2.0% | |
| LTM Mar 2026 | $3.17M USD | -100.0% | — | — | |
| LTM Mar 2026 | $1.36M USD | +926.5% | +60.6% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $1.1M USD | -5.4% | — | — |
| LTM Mar 2026 | $562.58K USD | +511.5% | — | 112.5% | |
| Peer median (excluding PRQR) | — | +50.9% | +56.9% | 116.0% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (60.8M) | (64.2M) | (27.74M) | (27.76M) | (40.52M) |
| Depreciation & Amortization | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M |
| Deferred Income Tax | 117K | 96K | (78K) | (197K) | 0 |
| Stock-Based Compensation | 6.22M | 2.87M | 3.11M | 2.54M | 0 |
| Change in Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Other Non-Cash Items | 1.11M | (4.8M) | (5.21M) | (474K) | 3.94M |
| Operating Cash Flow | (26.01M) | (68.51M) | 21.55M | (36.39M) | (50.71M) |
| Capital Expenditures | (484K) | (708K) | (1.37M) | (1.42M) | (979.75K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (17M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 17M | 0 |
| Other Investing Activities | 59K | 6K | 5.65M | (2.66M) | 0 |
| Investing Cash Flow | (425K) | (702K) | 4.28M | (4.07M) | (979.74K) |
| Debt Repayment | 26.84M | (45.05M) | (2.63M) | (1.58M) | (1.91M) |
| Common Stock Issued | 108.48M | 14.12M | 0 | 71.64M | 66.28K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | 34K | 354K | 223K | 75.19K |
| Financing Cash Flow | 136.83M | (30.89M) | (2.28M) | 70.28M | (1.76M) |
| Effect of Forex Changes | 1.29M | 7.35M | 599K | 673K | 14.15M |
| Net Change in Cash | 111.69M | (92.75M) | 24.15M | 30.48M | (39.3M) |
| Free Cash Flow | (26.5M) | (69.22M) | 20.18M | (37.81M) | (51.69M) |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.